Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

The MarginGuide: a medical device to improve the results of cancer surgery

Descripción del proyecto

Mejores resultados para el cáncer de boca gracias a la identificación de los límites del tumor con alta tecnología

La eliminación total de los tumores de boca es poco frecuente, ya que el límite del tumor se determina de forma visual y al tacto, lo cual genera estimaciones muy conservadoras. Eso suele llevar a más intervenciones quirúrgicas o tratamientos antineoplásicos que tienen una repercusión negativa en el pronóstico del paciente. La pyme SurGuide, con sede en los Países Bajos, ha desarrollado un nuevo dispositivo basado en la espectroscopia Raman para diferenciar el tejido sano del tejido canceroso en el tumor extirpado. Si no hay un margen de más de cinco milímetros de tejido sano (el criterio para la extirpación adecuada de tumores), se debe seguir eliminando. El proyecto MarginGuide, financiado con fondos europeos, respalda un estudio de viabilidad comercial y técnico que debería conducir a un plan comercial exitoso.

Objetivo

SurGuide is a medical device company which aims to improve the results of oral cancer surgery. In the operating room, the surgeon has to rely on his hands and eyes to distinguish tumour from healthy tissue. This is very difficult. In only 15% of the cases, the tumour is removed with an adequate margin. When after surgery, during histopathological assessment, an inadequate margin is detected, the patient will receive adjuvant treatment (i.e. radiotherapy, additional surgery). This often causes lasting additional morbidity, with a negative effect on the quality of life. A fast and reliable methodology is needed to assess tumour removal with adequate margin, during surgery. The MarginGuide is being developed to meet this clinical need. It is a novel tool based on Raman spectroscopy; an optical technology. The MarginGuide consists of a Raman spectroscopic work station, a user-interface, and a fiber-optic probe employing disposable fiber-optic needles. It will be used to rapidly inspect the resection surfaces of the tissue that has been removed by the surgeon and will pinpoint locations where additional tissue should be removed to obtain an adequate margin. A proof-of-concept instrument is currently being tested. SurGuide expects to raise the success rate of oral cancer surgery from the current 15% to over 50%. No other device is able to measure the surgical margin in oral cancer surgery, which gives SurGuide a unique market position and the possibility to gain a dominant market share. Although, this is an ideal starting point, some market barriers still exist. In this project, SurGuide carries out a feasibility assessment covering a business feasibility study and partly a technological feasibility study. The objective of the feasibility assessment is to refine the business plan and the implementation plan for successful commercialization and to optimize the optical technology for the MarginGuide.

Convocatoria de propuestas

H2020-EIC-SMEInst-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEInst-2018-2020-1

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

SURGUIDE BV
Aportación neta de la UEn
€ 50 000,00
Dirección
MARCONISTRAAT 16
3029 AK ROTTERDAM
Países Bajos

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
West-Nederland Zuid-Holland Groot-Rijnmond
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 71 429,00